Valens: Canaccord Lowers Price Target To $3.75

Earlier this month, The Valens Company (TSX: VLNS) reported their fiscal third-quarter financial results. The company reported net revenue of $20.99 million, up from the $18.76 million reported last quarter. Gross margins were 26.8% for the quarter compared to 22% last quarter, while adjusted EBITDA came in lower than last quarter at negative $6.18 million. The company reported a net loss of $12.8 million. Valens saw its SKU count go from 75 at the end of the first fiscal quarter to now 181 at the end of this quarter.

The Valens Company currently has 9 analysts covering the stock with an average 12-month price target of C$3.92, or 89% upside. Out of the 9 analysts, 1 has a strong buy rating, 7 have buys and 1 analyst has a hold rating. The street high sits at C$5.25 from Stifel-GMP, while the lowest comes in at C$2.50.

In a note, Canaccord Genuity lowered their price target to C$3.75 from $4.25 and speculative buy rating saying that after their first run-through the company is now focusing on margins. For the quarter, Canaccord forecasted revenue to be C$22.5 million.

Canaccord notes that this quarter included partial sales from Green Roads which accounted for C$4.7 million, so if you would back that out then sales would have declined by 12%. They write that this decline would be attributed to the company “transitioning away from smaller, underperforming B2B partners in favour of building deeper relationships with larger LPs.”

Onto gross margins, the company saw a 4.8% increase in gross margins, which can be partially attributed to the Green Roads inclusion. Canaccord writes, “Having now achieved critical mass for its SKU listings, VLNS plans to shift focus to driving margin expansion through automation, volume growth, and operational efficiencies.”


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Gold Trade Is Shifting From Margins to Growth | Geordie Mark – Blue Jay Gold

CopAur Minerals – This PEA Has A Mine Life of What?!

Ontario’s Fast Track to Silver Production Is Starting to Matter | Frank Basa – Nord Precious Metals

Recommended

Blue Jay Gold Launches 16,000 Metre Drill Program At Steller

Crossroads Gold Begins 2026 Exploration at Pambula, Reports Gold In Soil Up to 24.6 g/t

Related News

BMO Forecasts Bleak Results For Micron Technology

Micron Technology (NASDAQ: MU) is expected to report its fiscal fourth quarter results on September...

Saturday, September 24, 2022, 03:31:00 PM

Tilray: Analysts Leave Targets Unchanged After MedMen Investment

On August 17, Tilray (NASDAQ: TLRY) made the announcement that they formed a new limited...

Thursday, August 19, 2021, 01:03:00 PM

Nuvei Consensus Price Target Climbs $21 After Q2 Results Impress

On August 10, Nuvei Corporation (TSX: NVEI) reported its second quarter financial results. The company...

Sunday, August 15, 2021, 04:02:00 PM

Canaccord Genuity Raises Medipharm Labs’ Price Target To C$2.50

On Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European...

Tuesday, October 6, 2020, 01:29:18 PM

Antibe Therapeutics: Canaccord Initiates Coverage, Issues $1.50 Price Target

Recently, Canaccord Genuity’s Tania Gonsalves initiated coverage on Antibe Therapeutics (TSXV: ATE), a biotechnology company...

Tuesday, August 18, 2020, 01:46:28 PM